RCMI Coordinating Center (RCMI CC) Header Logo

Connection

William M. Southerland to Antineoplastic Combined Chemotherapy Protocols

This is a "connection" page, showing publications William M. Southerland has written about Antineoplastic Combined Chemotherapy Protocols.
  1. Zhao Y, Hao Y, Ji H, Fang Y, Guo Y, Sha W, Zhou Y, Pang X, Southerland WM, Califano JA, Gu X. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila). 2010 Jun; 3(6):787-96.
    View in: PubMed
    Score: 0.080
  2. Das JR, Fryar-Tita EB, Zhou Y, Green S, Southerland WM, Bowen D. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res. 2007 Nov-Dec; 27(6B):3791-9.
    View in: PubMed
    Score: 0.067
  3. Fryar-Tita EB, Das JR, Davis JH, Desoto JA, Green S, Southerland WM, Bowen D. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Anticancer Res. 2007 May-Jun; 27(3B):1393-9.
    View in: PubMed
    Score: 0.065
  4. Das JR, Fryar-Tita EB, Green S, Southerland WM, Bowen D. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. Anticancer Res. 2007 Mar-Apr; 27(2):825-33.
    View in: PubMed
    Score: 0.064
  5. Fryar EB, Das JR, Davis JH, Desoto JA, Laniyan I, Southerland WM, Bowen D. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy. Anticancer Res. 2006 May-Jun; 26(3A):1861-7.
    View in: PubMed
    Score: 0.060
  6. Das JR, Fryar EB, Epie NN, Southerland WM, Bowen D. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Res. 2006 May-Jun; 26(3A):1877-83.
    View in: PubMed
    Score: 0.060
  7. De Soto JA, Bowen D, Davis JH, Southerland WM, Hawkins M. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells. Anticancer Res. 2002 Mar-Apr; 22(2A):1007-9.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support